Aventis Faces Threat Of Generic Competition For Lovenox

Law360, New York (March 15, 2004, 12:00 AM EST) -- A U.S. biotechnology company headed for an initial public offering plans to produce a generic version of Aventis’ anti-blood clotting drug Lovenox.

Momenta Pharmaceuticals Inc., which filed with the Securities and Exchange Commission last week for an initial public offering worth an estimated $86.3 million, revealed in its filing that it expected to seek approval for a generic version of Lovenox in the next 12 months.

The company said it had already partnered the project with Sandoz, the generics arm of Novartis, to make the generic...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.